title: Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B' strains by recombinant Mycobacterium bovis BCG-based candidate vaccine.
abstract: The recombinant Mycobacterium bovis BCG (rBCG) vector-based vaccine secreting the V3 principal neutralizing epitope of human immunodeficiency virus type 1 (HIV-1) Japanese strain was reported to induce both humoral and cellular immune responses effectively [Proc. Natl. Acad. Sci. USA. 92 (1995) 10693]. The antigen-secreting rBCG system was applied to the V3 epitope of clade E HIV-1 in this study. The V3 sequence of 19 amino acids (aa) and 15aa fused with mycobacterial alpha-antigen was not secreted while 12aa and 11aa sequences were successfully secreted from BCG cells. Serum IgG from guinea pig which was immunized with 12aa epitope-secreting recombinant BCG neutralized the WHO reference strain as well as primary field isolates of clade E virus. The serum IgG could also neutralize Thai B (clade B') strains which possessed a conserved GPGQ motif in their V3 sequences. These data suggest that the rBCG construct secreting the 12aa epitope is implicated in the development of a prophylactic vaccine in Thailand in which both clade E and B' viruses are prevalent.
authors.affiliation: Central Research Laboratories, Ajinomoto Co., Inc., Suzuki-cho 1-1, Kawasaki-ku, Kawasaki 210-0801, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Chujoh
authors.forename: K
authors.initials: K
authors.lastname: Matsuo
authors.forename: H
authors.initials: H
authors.lastname: Yoshizaki
authors.forename: T
authors.initials: T
authors.lastname: Nakasatomi
authors.forename: K
authors.initials: K
authors.lastname: Someya
authors.forename: Y
authors.initials: Y
authors.lastname: Okamoto
authors.forename: S
authors.initials: S
authors.lastname: Naganawa
authors.forename: S
authors.initials: S
authors.lastname: Haga
authors.forename: H
authors.initials: H
authors.lastname: Yoshikura
authors.forename: A
authors.initials: A
authors.lastname: Yamazaki
authors.forename: S
authors.initials: S
authors.lastname: Yamazaki
authors.forename: M
authors.initials: M
authors.lastname: Honda
mesh_terms: D016915:AIDS Vaccines / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D000595:Amino Acid Sequence; D000818:Animals; D001500:BCG Vaccine / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D000939:Epitopes / Q000235:genetics; D005822:Genetic Vectors; D006168:Guinea Pigs; D015483:HIV Antibodies / Q000096:biosynthesis*; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000821:virology; D015497:HIV-1 / Q000145:classification* / Q000235:genetics / Q000276:immunology*; D006801:Humans; D008969:Molecular Sequence Data; D009163:Mycobacterium bovis / Q000235:genetics; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology; D013785:Thailand; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology / Q000494:pharmacology
chemical_list: D016915:AIDS Vaccines; D001500:BCG Vaccine; D000939:Epitopes; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments; D014614:Vaccines, Synthetic